Boehringer-Ingelheim is to cut the price of its antiretroviral drug nevirapine (Viramune) by 50% in low-income countries, the company’s chairman said today. However, the concessionary price offered by Boehringer will still be four times higher than the price offered by Indian generic manufacturers through the Clinton HIV/AIDS Initiative’s purchasing consortium.